Cresset Asset Management LLC bought a new position in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 20,911 shares of the company's stock, valued at approximately $251,000. Cresset Asset Management LLC owned 0.19% of Palvella Therapeutics as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of PVLA. Renaissance Technologies LLC bought a new position in Palvella Therapeutics in the 4th quarter worth about $256,000. BML Capital Management LLC purchased a new stake in shares of Palvella Therapeutics in the fourth quarter worth about $506,000. Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $171,000. Nantahala Capital Management LLC purchased a new position in Palvella Therapeutics during the fourth quarter valued at approximately $3,001,000. Finally, Adams Street Partners LLC bought a new stake in Palvella Therapeutics during the 4th quarter worth approximately $4,916,000. Hedge funds and other institutional investors own 40.11% of the company's stock.
Insider Buying and Selling at Palvella Therapeutics
In other Palvella Therapeutics news, Director George M. Jenkins bought 2,500 shares of Palvella Therapeutics stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $20.13 per share, with a total value of $50,325.00. Following the completion of the purchase, the director now owns 183,171 shares of the company's stock, valued at approximately $3,687,232.23. This represents a 1.38% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several research analysts have commented on PVLA shares. Canaccord Genuity Group cut their price target on shares of Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating for the company in a report on Friday, May 16th. TD Cowen started coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a "buy" rating and a $44.00 target price for the company. Stifel Nicolaus started coverage on Palvella Therapeutics in a research note on Wednesday, March 26th. They issued a "buy" rating and a $45.00 target price on the stock. Chardan Capital began coverage on Palvella Therapeutics in a research report on Wednesday, April 9th. They set a "buy" rating and a $50.00 price target for the company. Finally, Jones Trading started coverage on shares of Palvella Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $45.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $46.29.
Check Out Our Latest Report on PVLA
Palvella Therapeutics Stock Down 1.0%
Shares of PVLA stock traded down $0.23 on Wednesday, hitting $23.00. 46,537 shares of the company's stock traded hands, compared to its average volume of 68,311. The stock has a market cap of $253.99 million, a PE ratio of -1.90 and a beta of 0.10. The firm's fifty day moving average is $24.40. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $2.66. As a group, equities research analysts anticipate that Palvella Therapeutics will post -3.69 EPS for the current year.
Palvella Therapeutics Company Profile
(
Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Articles
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
